32 results about "Type IV collagen" patented technology

The invention provides recombinant IV type collagen and application thereof, and relates to the technical field of protein engineering. In the invention, an amino acid residue repetitive unit with good biological activity and stability in the human-derived IV-type collagen is found, and the amino acid residue repetitive unit is used as a core for repeating and constructing the recombinant IV-type collagen, so that the novel human-derived recombinant IV-type collagen with biological activity is obtained. The human-derived recombinant IV-type collagen provided by the invention is a small-molecular-weight protein, is easy to absorb by a human body, is good in safety, can remarkably promote secretion of collagen, also has the effects of promoting cell adhesion and cell migration, and has a good application prospect in the aspects of basement membrane repair and remodeling. A new functional component is provided for products for repairing and tightening the skin, resisting aging, resisting wrinkles, preserving moisture and the like.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

This invention provides the application of type IV collagen and its encoding gene in the prognostic assessment and treatment of nasopharyngeal carcinoma (NPC). Research has shown that high expression of type IV collagen and its encoding gene COL4A1 is significantly associated with lower T-cell infiltration in patients with recurrent NPC; compared to NPC patients with low expression of type IV collagen, those with high expression have worse LRRFS and OS; and the expression level of the type IV collagen encoding gene COL4A1 is significantly associated with worse PFS in NPC patients. Therefore, type IV collagen and its encoding gene COL4A1 can serve as specific prognostic biomarkers for assessing the prognosis of NPC patients. Furthermore, inhibiting the expression of type IV collagen can effectively inhibit the growth of NPC; therefore, agents that inhibit type IV collagen expression can be used as drugs to inhibit immune escape in NPC and for the treatment of NPC.

The present invention discloses a type IV collagen detection kit and a preparation method thereof, relating to the technical field of in vitro diagnosis. The kit comprises a reagent R1 and a reagent R2, wherein the volume ratio of the reagent R1 to the reagent R2 is 3:1. The present invention improves the sensitivity and accuracy of detection while ensuring the stability and repeatability of the kit through a carefully designed reagent formula, in particular the precise proportion of the components in the reagent R1, such as ammonium chloride, sodium azide, and Brij‑35. In particular, the reagent R1 introduces a natural plant extract, astragalus polysaccharide, and a proteinase K inhibitor as key components. The unique preparation method and the activity-promoting effect on type IV collagen hydrolase significantly enhance the biological activity of the kit, making the detection results more reliable. In addition, the latex particles coated with two paired mouse monoclonal antibodies used in the reagent R2 have high specificity and affinity, further improving the accuracy and sensitivity of detection.

Immunoassay methods for detecting HNE-generated fragments of the α3 or α4 chain of type IV collagen in a patient sample and their use for detecting and / or monitoring inflammatory bowel disease (IBD) or a particular level of severity of the disease in a patient are disclosed. Also disclosed are monoclonal antibodies and assay kits for use in the immunoassay methods.

The application relates to a preparation method and application of royal jelly acid double-wrapped bodies, and belongs to the technical field of cosmetics. The royal jelly acid double-wrapped body prepared by the application is obtained by co-wrapping royal jelly acid by phospholipid lipids and hydroxypropyl-beta-cyclodextrin, and the double-wrapping system of the hydroxypropyl-beta-cyclodextrin and the liposome improves the loading capacity of the royal jelly acid, has good stability, can significantly improve the solubility of the royal jelly acid, and is convenient for application in cosmetics; compared with pure royal jelly acid, the royal jelly acid double-wrapped body prepared by the application has more excellent skin permeability and more excellent effect of improving the content of type IV collagen of skin, and can provide mechanical support for skin and maintain the young state of skin.

Disclosed herein are medical products, including an implantable device coated with an extracellular matrix comprising Type IV collagen and laminin, wherein the implantable device comprises at least one member selected from the group consisting of sensors, meshes and cannulas, and the extracellular matrix contains no more than 0.024 mg / ml total concentration of glucose, amino acids and salts having a molecular weight of 2000 daltons or less. Corresponding systems and method also are disclosed.

The invention relates to the technical field of cosmetics, in particular to russula vinosa extract and a preparation method and application thereof.The preparation method comprises the steps that dried russula vinosa is smashed, production water is added, heating and stirring are conducted, filtering is conducted, filtrate is reserved, production water is supplemented into filter residues, heating and stirring are continued, filtering is conducted, filtrate is reserved, production water is supplemented into the filter residues again, and the russula vinosa extract is obtained; continuously heating, stirring and extracting, filtering, and retaining filtrate; combining the three filtrates, and carrying out solid-liquid separation to obtain a clear and transparent russula vinosa extracting solution; and concentrating and drying the russula vinosa extracting solution to obtain the russula vinosa extract. The method is simple in process and high in extraction efficiency, meanwhile, the content of type I collagen, type IV collagen and elastin can be remarkably increased on the cellular level by the russula vinosa extract with the concentration of 2 mg / mL, the density of collagenous fibers and elastic fibers can be remarkably increased on human skin explant tissue, and the russula vinosa extract has good anti-wrinkle and firming effects and is suitable for being used as a skin care product. A new raw material choice is provided for preparing the anti-wrinkle and firming cosmetics.

The application relates to the cosmetic technical field, in particular to a high-efficiency anti-aging composition and a skin care product containing the same. The high-efficiency anti-aging composition is prepared from the following raw materials in parts by mass: 12-15 parts of oil-based concentrated active ingredients, 25-35 parts of base collagen liquid, 15-18 parts of ikar, 12-16 parts of TWEEN 20, and 22-25 parts of isosorbide dimethyl ether. The oil-based concentrated active ingredients include safflower seed oil, acmella oleracea flower / leaf / stem extract, Astragalus membranaceus (Fisch.) Bunge root extract, ubiquinone and vitamin E. The base collagen liquid includes type XVII collagen, type VII collagen and type IV collagen. The composition can effectively reduce skin wrinkles, improve skin tightness and reduce skin sagging in a long term, and prevent skin aging, and realizes long-term anti-aging from epidermis to dermis.

This invention belongs to the field of renal pathology testing technology and discloses a method for detecting type IV collagen expression in renal biopsy tissue, comprising the following steps: dewaxing and hydrating paraffin sections of renal biopsy tissue to obtain processed tissue sections; adding the processed tissue sections to a repair solution, heating to boiling, and then cooling to room temperature to obtain repaired tissue sections; adding protease to the repaired tissue sections for enzymatic digestion to obtain enzymatically digested tissue sections; adding a primary antibody to the enzymatically digested tissue sections for preliminary incubation, followed by adding a fluorescein-labeled secondary antibody against the primary antibody for further incubation. This method for detecting type IV collagen expression in renal biopsy tissue is applicable to cases where renal biopsy tissue lacks glomeruli or has too few glomeruli to detect type IV collagen expression. It has high specificity and can provide a new detection method for Alport syndrome in cases where renal biopsy tissue lacks glomeruli.

The present application relates to a kind of compositions for improving skin color and its application, belong to the field of cosmetics.The present application provides a kind of composition, the composition includes recombinant humanization type IV collagen and lavender exosome, the amino acid sequence of the recombinant humanization type IV collagen is as shown in SEQ ID NO.1, both compound use, can increase the expression of heat shock protein, improve cell viability under heat stress, inhibit the expression of endothelin and the production of glycation product, to improve the effect of skin skin color, and both have synergistic effect.The composition of the present application reduces the amount of recombinant humanization type IV collagen under the premise of achieving similar effects by using lavender exosome, significantly reduces the application cost of recombinant humanization type IV collagen.

The invention belongs to the technical field of oral care, and discloses application of beta-hydroxybutyric acid and an oral care product. The invention provides a novel application of beta-hydroxybutyric acid. The beta-hydroxybutyric acid is found to be capable of effectively promoting the expression of I-type collagen, III-type collagen, IV-type collagen and VII-type collagen; therefore, the oral mucosa healing can be effectively promoted, the oral mucosa barrier is repaired and strengthened, and the oral mucosa repair and gingival repair are promoted; and the oral care product with any one of the effects of promoting oral mucosa healing, repairing and strengthening oral mucosa barrier, promoting oral mucosa repair and repairing gingiva is formed.

The invention belongs to the technical field of medicines, and particularly relates to a mitochondria-rich extracellular vesicle derived from periodontal cells and application of the extracellular vesicle in ischemic brain injury. The extraction method of the extracellular vesicles comprises the following steps: (1) chopping a cerebral cortex part, adding type II collagenase and DNaseI for digestion, and then adding a gradient separation medium for separation to obtain pericytes; (2) spreading the periodontal cells on a culture dish coated with IV-type collagen, and culturing in a periodontal cell culture medium; and (3) when the confluence degree of the cells reaches 80%-90%, replacing the cell culture medium with a fresh culture medium without exosome FBS, reoxygenating the cells for 24 hours after OGD treatment, collecting culture supernatant, and centrifuging the culture supernatant to obtain the extracellular vesicles. It is found for the first time that the PC-EVs obtained after OGD stress can protect the brain from ischemic stroke injury, and the PC-EVs have important reference significance for researching related drugs for treating ischemic brain injury.

The application provides a cyclic hexapeptide compound, a preparation method and application thereof. The cyclic hexapeptide compound has the structure of formula (I), has higher stability and bioavailability, can significantly promote the secretion of collagen, especially type I collagen, type III collagen and type IV collagen, has a tightening effect, and can be applied to cosmetics to maintain the structure and elasticity of skin and promote skin health.

The invention discloses a preparation method and application of recombinant humanized IV-type collagen, particularly discloses an optimized nucleotide sequence for coding M6 protein, and discovers that a carrier containing a plurality of optimized nucleotide sequences and a carrier containing CPB and KEN2 nucleotide sequences are co-transformed into cells through a large amount of screening, so that the recombinant humanized IV-type collagen is obtained. The expression quantity of the M6 protein can be obviously improved, and the obtained M6 has very good cell proliferation and migration activity.

An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.

Described herein is an assay for measuring protease-mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment.

Provided are a method for screening a truncated bioactive peptide of type IV collagen by using a bioinformatics method, a truncated peptide obtained by means of the method, and an application thereof. Further provided is a method for obtaining the truncated peptide by means of fermentation using a yeast expression system.

The embodiment of the present application discloses a type IV collagen recombinant antigen and application. From N terminal to C terminal, the amino acid sequence fragments shown as SEQ ID NO. 1, the amino acid sequence fragments shown as SEQ ID NO. 2 and the amino acid sequence fragments shown as SEQ ID NO. 3 are sequentially spliced. The multi-subunit fragments α2 (7S), α3 (724-778) and α5 (NC1) are recombined in the present application, so that the recombinant IVC antigen with considerable expression amount and stability can be obtained, the antibody affinity after immunization can be increased, and the IVC antibody with higher titer can be obtained.

The present application belongs to the technical field of cosmetics, and particularly relates to a recombinant humanized collagen composition, a preparation method and application. The present application first reports a recombinant humanized collagen composition, which is based on the independently developed recombinant humanized collagen, and through compounding chitosan, ectoine and other components, the application scene of the recombinant type IV collagen is effectively expanded; and the composition itself can reduce the ability of melanocytes to synthesize melanin, has the ability to scavenge free radicals, and can also reduce the amount of preservatives in the composition, effectively maintain the stability of the recombinant type IV collagen. The recombinant humanized collagen composition can be used for daily skin care, and can also help the recovery after medical and aesthetic surgery, and therefore has good practical application value.

This invention discloses an antibody or its antigen-binding fragment that targets the α5 chain of type IV collagen, belonging to the field of antibody and related technologies, and can be applied to the diagnosis of Alport syndrome.

The application discloses a kind of recombinant humanized IV type collagen M2 or M4, the nucleic acid molecule sequence of coding the recombinant humanized IV type collagen M2 is as shown in SEQ ID NO.1, the nucleic acid molecule sequence of coding the recombinant humanized IV type collagen M4 is as shown in SEQ ID NO.3.The recombinant humanized IV type collagen M2 or M4 provided by the application expresses and purifies recombinant humanized IV type collagen using genetic engineering technology and biological fermentation method, which has the advantages of single end product composition, less impurities, no animal virus, no immune risk and convenient industrialization, etc., can effectively improve the cell proliferation and migration activity, and can be widely applied in food, cosmetics, health products and pharmaceutical products field.

An object is to provide a drug that effectively treats a vascular disorder caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell. Provided are [1] a therapeutic agent for a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [2] a therapeutic agent for a disease caused by excessive synthesis and secretion of a type IV collagen protein; [3] a pharmaceutical composition for treatment of a vascular disorder associated with excessive synthesis and secretion of a type IV collagen protein; [4] a pharmaceutical composition for treatment of a disease caused by excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell; and [5] an agent that inhibits excessive synthesis and secretion of a type IV collagen protein from a vascular endothelial cell, each of [1] to [5] containing sirolimus as an active ingredient.

The invention discloses a composition with a basilar membrane repairing effect and preparation and application of the composition, and the composition is prepared from the following components in percentage by mass: 0.01%-0.2% of recombinant IV type collagen, 0.4%-4.0% of yeast fermentation product extract, 0.01%-0.2% of acetyl tetrapeptide-9, 0.01%-0.2% of acetyl tetrapeptide-11, 4%-10% of 1, 2-hexanediol, 0.01%-0.5% of ethylhexylglycerin and the balance of water. The composition has the advantages that the skin cell activity can be greatly improved, and cell migration is promoted; and the repair of the basement membrane is effectively protected and promoted through the ways of remarkably promoting the growth of the components of the basement membrane, enhancing the skin barrier, resisting inflammation, relieving and the like.

The present application relates to the four type collagen as the specific molecular target point in the targeted diagnosis and / or treatment of aortic dissection / aneurysm. The COLIV targeting peptide segment and its derivative are synthesized independently, the occurrence of aneurysm / dissection is monitored by monitoring the activation of endothelial cells, the monitoring mode is one or several of the following: ultrasonic detection, MRI detection, CTA detection, fluorescence imaging detection; in addition, the COLIV targeting peptide segment can also be used as a molecular target point of a targeted drug delivery system, to ensure that the disease site has a higher blood drug concentration and smaller toxic side effects, the drug is: a drug administered through the gastrointestinal tract, a drug administered by intravenous injection, a drug administered by subcutaneous embedding, preferably a drug administered by subcutaneous embedding.

A method for biosynthesizing the human structural material type IV collagen is provided. Provided herein is a recombinant collagen comprising a sequence such as that shown in SEQ ID NO:1. The recombinant collagen has good cell adhesion activity. The method herein utilizes genetic engineering technology to produce recombinant collagen, overcoming the deficiencies of the prior art.

The invention discloses a microneedle / GelMA hydrogel composite hernia patch and a preparation method thereof, the patch comprises a microneedle array layer and GelMA hydrogel, and the GelMA hydrogel covers and adheres to the root of a microneedle head. The microneedle array layer is used for realizing tissue fixation and local drug delivery, and the GelMA hydrogel is subjected to enzymatic crosslinking by an HRP / H2O2 system to form a stable structure and has good flexibility and wet adhesion performance. By combining the biodegradability and tissue integration characteristics of the IV type collagen and the adjustable mechanical and biological adhesion characteristics of the GelMA hydrogel, a minimally invasive, stable and degradable hernia repair scheme is realized, and the hydrogel can be firmly attached to the tissue surface without suture, can be gradually degraded and absorbed after operation, reduces foreign body reaction and organ adhesion, and has a good application prospect. The infection and recurrence risks are obviously reduced, and excellent biocompatibility and clinical application prospects are achieved.

The application discloses a heat-resistant and stable recombinant humanized type VII collagen as well as a preparation method and application thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the recombinant humanized type VII collagen is formed by connecting four type VII collagen functional fragments in series, and the coding nucleotide is obtained by Pichia pastoris preference optimization design. The sequence is inserted into a pPIC9K plasmid to construct a recombinant vector, and the engineering bacteria are obtained by electric transformation of Pichia pastoris GS115. The target protein rhCOL7 is prepared through fermentation and purification. The rhCOL7 protein has excellent thermal stability, can resist 115 DEG C moist heat sterilization, has no obvious degradation after being placed at 60 DEG C for 60 days, can significantly promote cell proliferation, migration and adhesion, and can specifically interact with type IV collagen. The application realizes efficient preparation of the recombinant humanized type VII collagen, the activity of which is high and the stability of which is good, and the recombinant humanized type VII collagen can be widely applied to the preparation of wound repair drugs, biological repair materials and cosmetics.

This invention provides a complex protein composition, product, and application for improving skin condition. The complex protein composition includes type IV collagen, type VII collagen, type XVII collagen, laminin 332, and fibronectin. This complex protein composition helps to improve skin condition, delay the appearance of aging, reduce wrinkles, and improve sagging. Simultaneously, it plays a positive role in repairing and supporting the skin barrier and extracellular matrix structure, which is beneficial for maintaining the stability and orderly remodeling of the skin microenvironment.

This invention provides ACTA2 + MCAM + Application of cells in nasopharyngeal carcinoma patients' recurrence, radiotherapy efficacy and prognostic assessment, and treatment. This invention, based on extensive research, has discovered that ACTA2... + MCAM + Cells can serve as specific biomarkers for assessing nasopharyngeal carcinoma recurrence, radiotherapy efficacy, and prognosis; detection of ACTA2 is indicated. + MCAM + The cellular reagent can be used to prepare products for assessing nasopharyngeal carcinoma recurrence, radiotherapy efficacy, and prognosis. Furthermore, the ACTA2... + MCAM + Cells promote radioresistance in nasopharyngeal carcinoma cells by secreting type IV collagen that binds to the ITGA2 integrin receptor on the surface of the cells. This activation of the downstream PI3K-AKT signaling pathway leads to the formation of this receptor. Therefore, specific clearance of ACTA2 is crucial. + MCAM + Cells, inhibiting ACTA2 + MCAM + Cellular production of type IV collagen and blocking the binding of type IV collagen to the ITGA2 integrin receptor on the surface of tumor cells, as well as inhibiting the downstream PI3K-AKT signaling pathway, can effectively reverse the radiotherapy resistance of nasopharyngeal carcinoma and improve the efficacy of radiotherapy.